The Dry Eye Syndrome Treatment Market To Reap Rewards By Reaching US$ 4.2 Bn, Wi

Posted by Ashish on April 13th, 2021

Dry eye syndrome results in irritated and burning eyes due to lack of tear production and moisturization. Meibomian Gland Dysfunction has more prevalence among the geriatric population. The market consists of several products used in therapeutics, such as cyclosporine, topical corticosteroids, punctal plugs, omega supplements, and the especially popular artificial tears. Fast approval and launch of products used for dry eye treatment is expected to drive market growth in future.

Several key market players are focused on collaborative product development, innovation, and expansion of product portfolio. For instance, in October 2020, Santen Pharmaceutical and Orbis International announced their long-term collaboration for ten years to contribute toward the increasing burden of eye diseases in low- and middle-income countries.

Rapidly increasing number of eye care centers due to rising focus on primary eye care is expected to propel dry eye syndrome treatment market growth. Increasing number of LASIK surgeries, which is one of the major causes leading to dry eyes, is estimated to further drive market growth over the coming years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/32300

Companies covered in Dry Eye Syndrome Treatment Market Report

  • Allergan Plc.
  • Novartis AG
  • Otsuka Pharmaceutical Co.,Ltd.
  • Santen Pharmaceutical Co Ltd.
  • Bausch Health Companies Inc.
  • Akorn, Inc.
  • Johnson & Johnson, Inc.
  • Thea Pharmaceuticals Limited
  • OASIS Medical
  • Altaire Pharmaceuticals Inc.
  • Boiron USA
  • Similasan Corporation
  • Scope Ophthalmics Ltd.
  • Reckitt Benckiser Group PLC
  • Medicom Healthcare Ltd
  • FDC Limited.
  • Lupin Limited
  • Jamjoom Pharmaceuticals Co.
  • Sentiss Pharma Private limited

Like it? Share it!


Ashish

About the Author

Ashish
Joined: September 12th, 2019
Articles Posted: 582

More by this author